At a glance
- Originator Merck & Co
- Class Antiasthmatics
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 27 Feb 1997 No-Development-Reported for Asthma (Unknown route)